Frazier Life Sciences Management, L.P. 89bio, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in 89bio, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 1,000,000 shares of ETNB stock, worth $7.98 Million. This represents 0.4% of its overall portfolio holdings.
Number of Shares
1,000,000
Previous 1,000,000
-0.0%
Holding current value
$7.98 Million
Previous $8.01 Million
7.62%
% of portfolio
0.4%
Previous 0.47%
Shares
2 transactions
Others Institutions Holding ETNB
# of Institutions
158Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$121 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$113 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$63.8 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$58.9 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$56 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $371M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...